Owkin is a French-American startup that deploys AI and Federated Learning for medical research. The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board.
It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York. We combine cutting-edge machine learning and biology to advance drug discovery. We blend human insight with safe and fast data access to train high-performance models. Our cutting-edge machine learning methodologies de-risk and accelerate clinical trials. Building useful clinical tools to identify patients and boost their access to better treatment options.
B2B
51 to 100
N/A
US $74.1M
Scaling Up
2016
Pharmaceuticals and Medical Products
Managed Health Care
Health Care Facilities & Hospitals
Biotechnology
Treatment
Diagnostic Tool
Increase Efficiency
Increase Productivity
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
Knowledge Representation and Reasoning
Software
Biostatistician/Clinical Data Scientist
Paris, Paris
Machine Learning Scientist - Medical Imaging - Intern
Paris, Paris
Machine Learning Engineer
Paris, Paris
Quality Assurance Intern
Paris, Paris
Stage/Alternance Achats
Paris, Paris
2
2
$115M
Company was founded 2016 and it took almost 5 years (Nov 2021) to raise first external round
Interested in researching Owkin?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Owkin